Indivior Pharmaceuticals, Inc. (INDV)
Nasdaq: INDV · Pharmaceutical Preparations · North Chesterfield, VA · filing with the SEC since 2014
Income statement, as filed
In millions of US dollars (USD), as filed; per-share figures in US dollars; share counts in millions. The fiscal year ends in December.| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Period ending | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 |
| Report filed | Feb 26, 2026 | Mar 3, 2025 | Mar 6, 2024 | · |
| Revenue | 1,239 | 1,188 | 1,093 | 901 |
| Cost of revenue | 246 | 231 | 174 | 151 |
| Gross profit | 994 | 957 | 919 | 749 |
| Research and development | 97 | 107 | 116 | 74 |
| Selling, general and administrative | 634 | 612r | 565r | 469 |
| Total operating expenses | · | 919r | 1,072r | 831 |
| Operating income | 262 | 38r | -152r | -81 |
| Interest expense | 45 | 41 | 35 | 27 |
| Interest and investment income | 22 | 23 | 43 | 19 |
| Income before income taxes | 239 | 20r | -145r | -89 |
| Income tax expense | 29 | 13r | -19r | -44 |
| Net income | 210 | 7r | -126r | -44 |
| Earnings per share, basic | 1.68 | 0.05r | -0.92r | -0.32 |
| Earnings per share, diluted | 1.64 | 0.05r | -0.92r | -0.32 |
| Weighted average shares, basic | 125 | 132 | 137 | 139 |
| Weighted average shares, diluted | 128 | 133 | 137 | 139 |
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it sold
us-gaap:RevenueFromContractWithCustomerExcludingAssessedTaxCost of revenue what it cost to make or buy what it sold
us-gaap:CostOfGoodsAndServicesSoldGross profit revenue less the cost of what it sold
us-gaap:GrossProfitResearch and development spent on inventing what it sells next
us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCostSelling, general and administrative the cost of selling and of running the company
us-gaap:SellingGeneralAndAdministrativeExpenseTotal operating expenses the running costs together
us-gaap:OperatingExpensesOperating income profit from running the business, before interest and tax
us-gaap:OperatingIncomeLossInterest expense what its borrowing cost
us-gaap:InterestExpenseNonoperatingInterest and investment income what its cash and investments earned
us-gaap:InvestmentIncomeInterestIncome before income taxes profit before tax
us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterestIncome tax expense tax charged on the period's profit
us-gaap:IncomeTaxExpenseBenefitNet income the profit or loss that belongs to the company's shareholders
us-gaap:NetIncomeLossEarnings per share, basic net income per share outstanding
us-gaap:EarningsPerShareBasicEarnings per share, diluted net income per share, counting every share that could be issued
us-gaap:EarningsPerShareDilutedWeighted average shares, basic the average count of shares outstanding
us-gaap:WeightedAverageNumberOfSharesOutstandingBasicWeighted average shares, diluted the average count with every share that could be issued
us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding